Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief.

Abstract

Induction chemotherapy (IC) in locally advanced head and neck squamous cell carcinoma (LA HNSCC) has been used for decades. However, its role is yet to be clearly defined outside of larynx preservation. Patients with high risk of distant failure might potentially benefit from sequential treatment. It is now widely accepted that TPF (docetaxel, cisplatin, and fluorouracil) is the standard IC regimen. Essays that have compared this approach with the standard of care, concurrent chemoradiotherapy (CCRT), are mostly inconclusive. Radiotherapy (RT) can be used in the post-IC setting and be sensitized by chemotherapy or cetuximab. Again, no consensus exists but there seems to be trend in favor of potentiation by cisplatin. Less toxic schemes of IC are tested as toxicity is a major issue with TPF. IC might have an interesting role in human papilloma virus (HPV)-related LA HNSCC and lead to CCRT de-escalation.

• Authors: Andy Karabajakian, Max Gau, Thibault Reverdy, Eve-Marie Neidhardt, Jérôme Fayette
• Journal: Cancers (Cancers (Basel)) Vol. 11 Issue 1 (Dec 22 2018) ISSN: 2072-6694 [Print] Switzerland
• PMID: 30583519 (Publication Type: Journal Article, Review)